New research indicates that individuals who survived COVID-19 infection and those who died exhibited antibody responses that were primarily directed against different SARS-CoV-2 proteins.
Newer, Dominant SARS-CoV-2 Variant Three to Six Times More Infectious than Previous Dominant Variant
Besides addressing the question of infectivity, the new research presents geographic information about the rise of the new variant, G614, and the relative decline of the previously dominant variant, D614, across the globe.
More than 40,000 HCPs consented to testing with 13% (5,523) testing positive for antibodies. The positive sample pool comprised 11,468 (28.4% of positive tests) and 3,746 physicians (9.3%).
The team, led by Dan Jacobson of the Department of Energy's Oak Ridge National Laboratory, found that genes in the bradykinin system were excessively activated in the lung fluid cells of COVID-19 patients.
The study, called the Adaptive COVID-19 Treatment Trial 3 (ACTT 3), is anticipated to enroll more than 1,000 hospitalized adults with COVID-19 at as many as 100 sites in the United States and abroad.
The researchers found that one in three people with no prior exposure to SARS-CoV-2 nonetheless has T-helper cells capable of recognizing the virus. The likely reason for this is that SARS-CoV-2 shares certain structural similarities with other coronaviruses.
Research from the Spanish National Cancer Research Center (CNIO) and the Hong Kong University of Science and Technology (HKUST) shows that a subset of patients acquires a specific genetic alteration that can evade treatment from a combination of chemotherapy and radiotherapy.
Sema4 Signal is a family of products and services providing data-driven precision oncology solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.
The researchers found that population distribution of the disease-associated genetic variants differed depending on a person’s ethnic origin. Some of the variants in the ACE2 gene were linked to cardiovascular and lung conditions, whereas some in the TMPRSS2 gene were linked to different cancers.
Cancer patients who have low levels of circulating tumor (ct)DNA before starting treatment with immunotherapy are more likely to have a positive response to the treatment, according to research from the University of Toronto.
The researchers from Chongqing Medical University in Chongqing, China, also found that people’s antibody response to SARS-CoV-2 may diminish rapidly after infection, which may have implications for the interpretation of negative serological results.
The study showed that down-regulated genes appear to be involved in the abnormal muscle development and heart problems that are common in people with Down syndrome. Further, decreased expression of such genes interferes with solid tumor formation and growth.
Custom computer programs processed millions of genetic sequences to compare the antibody repertoire from B cells, depending on whether the microbes stay in the intestine, or whether they reach the bloodstream. In both cases, the antibody repertoire is altered, but in rather different ways depending on how the exposure occurs.
The research team’s findings suggest that inflammatory proteins produced during COVID-19 infection make platelets hyperreactive and likelier to form blood clots via platelet to platelet and platelet to leukocyte interactions.
Evidence about the effects of the novel severe coronavirus on the heart is growing. In one recent single-center report of 416 patients hospitalized with COVID-19, 19.7% had evidence of cardiac injury.
This study provides detailed demographic and geographic information about persons who were tested during the first five weeks of the outbreak, information that can better help define the risk of contracting the virus.
TRACK will recruit 400 people diagnosed with any rare cancer, which is defined as incidence of six per 100,000 people, per year, in the U.S. The study will focus on cholangiocarcinoma and cancer of unknown primary due to the promise of precision approaches in these subsets.
The kinase enzyme, called TBK1, plays a central role in regulating the degradation and clearance of the huntingtin protein and introduces chemical modifications that block its aggregation.
Proteomics and metabolomics may lag behind genomics in providing clinically actionable insights today, but the future is bright.
Results from the early blood tests showed that those that had poor outcomes from oxygen deprivation during birth could be predicted based on changes in the expression of 855 genes in the blood shortly after birth.
Findings from the new study could point to methods for identifying diseases and predicting their behaviors that are faster, simpler, less expensive, and more accurate than current standard techniques.
The researchers revealed for the first time a mutation in a protein called MTP that blocks the loading of triglycerides, but not phospholipids, onto ApoB, or “bad cholesterol.”
The kit is designed for purification of circulating cfNDA and uses silica coated paramagnetic particles to purify cfDNA from less than 1 mL to greater than 10 mL of serum or plasma.
Using vaso-occlusive episodes (VOEs) of sickle cell disease (SCD) as a vascular disease model, researchers at Albert Einstein College of Medicine discovered that the gut plays a critical role in provoking episodes of VOEs.
An exclusive Clinical OMICs conversation with the director of Genomes2People, Robert Green, M.D., MPH.